10-Q: Theriva Biologics Reports Positive VCN-01 Trial Data

Theriva Biologics announced positive clinical trial results for its lead oncology candidate VCN-01 in pancreatic cancer and retinoblastoma, while facing significant liquidity challenges.

Summary

• Reported a net loss of $13.1 million for the three months ended June 30, 2025, compared to $8.3 million for the same period in 2024.
• Accumulated deficit reached $352.4 million as of June 30, 2025.
• Cash and cash equivalents were $12.1 million as of June 30, 2025, and approximately $9.5 million in early August 2025.
• General and administrative expenses increased by 662% to $11.2 million for the three months ended June 30, 2025, primarily due to a $9.2 million increase in contingent consideration fair value.
• Research and development expenses decreased by 34% to $2.0 million for the three months ended June 30, 2025, mainly due to lower clinical trial and manufacturing costs for VCN-01 and SYN-004.
• Positive topline outcomes from the VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC) were announced on May 7, 2025, showing improved median overall survival (10.8 months vs. 8.6 months) and progression-free survival (7.0 months vs. 4.6 months).
• Definitive data from the investigator-sponsored Phase 1 study of VCN-01 in refractory retinoblastoma patients were presented on May 27, 2025, indicating VCN-01 was well tolerated with promising antitumor activity.
• Secured $6.9 million in net proceeds from a public offering in May 2025, along with $1.7 million from a Spanish R&D rebate program and a $1.4 million loan for the THERICEL project.
• Management believes current cash will fund operations into the first quarter of 2026, but not for the next twelve months from the filing date.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the clinical trial results for VCN-01 are highly positive and represent significant scientific progress, the severe financial distress, including the 'going concern' warning, limited cash runway, and the need for substantial additional capital, introduces significant risk and offsets the clinical successes. The deferral of a milestone payment further underscores the liquidity challenges.

Positives

• VCN-01 VIRAGE Phase 2b trial in metastatic PDAC showed positive topline outcomes, including improved median overall survival (10.8 months vs. 8.6 months for SoC) and progression-free survival (7.0 months vs. 4.6 months for SoC).
• The median duration of response (DoR) in the VCN-01+SoC arm for PDAC doubled to 11.2 months compared to 5.4 months in the SoC control arm.
• Patients receiving a second dose of VCN-01 in the PDAC trial showed a greater increase in overall survival (14.8 months vs. 11.6 months for SoC only in a subgroup), suggesting additional benefit.
• VCN-01 was well tolerated in the VIRAGE Phase 2b trial, with adverse events being less frequent and of reduced grade after the second dose.
• The Phase 1 study of VCN-01 in refractory retinoblastoma patients demonstrated VCN-01 was well tolerated with promising antitumor activity, including eye preservation with vision in 3 out of 5 partial response patients.
• VCN-01 received FDA Fast Track Designation and Orphan Drug Designation for pancreatic cancer, and Rare Pediatric Drug Designation for retinoblastoma.
• The company received an exclusive, worldwide technology license and related patents for VCN-01 in retinoblastoma treatment following positive study outcomes.
• Secured $6.9 million in net proceeds from a public offering in May 2025, providing some capital for operations.
• Received $1.7 million from a Spanish government R&D rebate program and a $1.4 million loan for the THERICEL project, supporting manufacturing and AAV therapy development.

Negatives

• Reported a significant net loss of $13.1 million for the three months ended June 30, 2025, an increase from $8.3 million in the prior year period.
• Accumulated deficit increased to $352.4 million as of June 30, 2025, indicating substantial historical losses.
• Cash and cash equivalents of $9.5 million as of early August 2025 are not sufficient to fund operations for the next twelve months from the filing date.
• The company's auditors' report contains an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• General and administrative expenses increased significantly by 662% due to a $9.2 million fair value adjustment to contingent consideration, reflecting an increased obligation.
• Enrollment for Cohort 3 of the SYN-004 Phase 1b/2a clinical trial is not anticipated to commence without additional grant funding or a licensee/partner, indicating a delay in this program.
• The option for an exclusive license to intellectual property related to SYN-020 with Massachusetts General Hospital expired unexercised on July 1, 2024, limiting future development options for this asset.
• A $6 million milestone payment to Grifols related to VCN-01 PDAC Phase 2b trial achievement has been deferred, with $5 million contingent on a future licensing or business development transaction, highlighting liquidity constraints.

Risks

• Recurring losses from operations and a significant accumulated deficit raise substantial doubt about the ability to continue as a going concern.
• Insufficient capital to fund operations beyond the first quarter of 2026, requiring significant additional financing for future clinical trials.
• No assurance that additional debt or equity financing will be available in sufficient amounts or on acceptable terms, or at all.
• Failure to obtain additional funding may force delays, reductions, or elimination of development programs, or cessation of operations.
• Future equity financings will dilute the ownership interest of existing stockholders.
• Debt financing, if available, may involve restrictive covenants that could impact business operations.
• Ability to raise capital through the ATM Sales Agreement is limited by SEC rules due to the market value of common stock held by non-affiliates being less than $75 million.
• May be required to seek collaborators for product candidates at an earlier stage and on less favorable terms than desirable.
• Changes to trade policy, including tariffs and customs regulations, or failure to comply, could adversely affect business and financial condition.
• Global security concerns (e.g., Ukraine/Russia, Middle East conflicts) could disrupt supply chains and impact R&D costs.
• Increasing inflation could raise operating costs for the business.

Future Outlook

The company anticipates research and development expenses to increase as it completes the VIRAGE Phase 2b clinical trial of VCN-01 and plans for a potential Phase 3 clinical trial of VCN-01 in PDAC, advances the VCN-01 program in retinoblastoma, expands GMP scale-up manufacturing activities for VCN-01, and continues supporting other preclinical and discovery initiatives. The company does not have sufficient capital to fund its operations beyond the first quarter of 2026 and will require additional funding for future clinical trials, which are expected to be larger and more costly. It is actively pursuing additional equity or debt financing, as well as partnerships and collaborations, but there is no assurance such capital will be available on acceptable terms or at all. The company intends to focus capital on VCN-01 clinical trials and will not fund further internal development of SYN-004 or SYN-020 without a partner or grant funding.

Management Comments

• Management believes that current cash on hand of $9.5 million in early August 2025 will be sufficient to fully execute its plans into the first quarter of 2026.
• Management anticipates current cash will allow it to cover overhead costs, manufacturing costs for near-term clinical supply and limited research efforts.
• Management believes its plan, which is focused on the advancement of VCN-01, will allow us to meet our financial obligations, further advance key products, and maintain our planned operations.
• Management does not anticipate that enrollment for the third cohort of the SYN-004 Phase 1b/2a clinical trial will commence unless grant funding or a licensee/partner is obtained.
• Management is actively pursuing additional equity or debt financing in the form of either a private placement or a public offering as well as partnerships and other collaborations.

Industry Context

Theriva Biologics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on oncology with its oncolytic adenovirus platform. The positive Phase 2b results for VCN-01 in pancreatic cancer, a notoriously difficult-to-treat malignancy, are significant and could position the company favorably within the oncolytic virus therapy landscape. The receipt of FDA Fast Track and Rare Pediatric Drug Designations, along with EMA Orphan Medicinal Product Designation, underscores the high unmet medical need in its target indications and could accelerate regulatory pathways. However, the company's persistent 'going concern' warning and reliance on external financing for continued operations are common challenges for clinical-stage biotechs that do not yet generate revenue, placing it in a financially precarious position relative to more established pharmaceutical companies or those with commercialized products.

Comparison to Industry Standards

• VCN-01's median Overall Survival (OS) of 10.8 months in metastatic PDAC (VIRAGE Phase 2b) compares favorably to historical benchmarks for gemcitabine/nab-paclitaxel standard-of-care (SoC), which typically ranges from 8.5 to 9.0 months in similar patient populations. For example, the MPACT trial, which established gemcitabine/nab-paclitaxel as a first-line therapy, reported a median OS of 8.5 months.
• The Progression-Free Survival (PFS) of 7.0 months for VCN-01+SoC is also an improvement over the 4.6 months observed in the SoC arm, and generally exceeds the 5.5 months reported in the MPACT trial for gemcitabine/nab-paclitaxel alone.
• The doubling of median Duration of Response (DoR) to 11.2 months with VCN-01+SoC, compared to 5.4 months for SoC, suggests a more durable response, which is a critical factor in cancer treatment efficacy.
• The observed increase in OS to 14.8 months for patients receiving two doses of VCN-01 and 4+ cycles of SoC, compared to 11.6 months for SoC alone in a subgroup, indicates a potential dose-dependent benefit, which is a strong signal for further development.
• In retinoblastoma, the preservation of vision in 3 out of 5 partial response patients treated with intravitreal VCN-01 is a significant outcome, as enucleation (eye removal) is often the only recommended treatment for refractory cases. This outcome is highly competitive with other emerging therapies aiming for eye preservation in advanced retinoblastoma.
• The company's cash runway into Q1 2026, coupled with a 'going concern' warning, is typical for early-stage biotechs but falls short of the 12-18 month runway often preferred by institutional investors for stability.

Related Party Transactions

• Compensation of MaryAnn Shallcross (wife of Steven Shallcross, CEO/CFO) as Director of Clinical Operations: $39,000 for the three months ended June 30, 2025, and $78,000 for the six months ended June 30, 2025.
• Grant of an option to purchase 25,000 shares of Common Stock to MaryAnn Shallcross, valued at $27,000, during the three months ended June 30, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises. The 'going concern' warning indicates a high risk of value impairment if additional funding is not secured. Positive clinical data for VCN-01 could lead to future value creation if commercialized.
• **Employees**: Continued operations and job security are dependent on the company's ability to raise additional capital. Clinical progress may offer morale boosts and future opportunities.
• **Customers (Future)**: Potential for new therapeutic options for difficult-to-treat cancers like pancreatic cancer and retinoblastoma if VCN-01 successfully completes trials and gains approval.
• **Suppliers/Creditors**: Risk of delayed payments or non-payment if the company fails to secure adequate funding. The deferral of the Grifols milestone payment is an example of this impact.
• **Regulatory Authorities**: The company is actively engaging with FDA and EMA, indicating adherence to regulatory pathways for drug development.

Next Steps

• Prepare the Clinical Study Report (CSR) for the VIRAGE Phase 2b clinical trial of VCN-01 in PDAC.
• Finalize the CSR for the Phase 1 investigator-sponsored trial evaluating intravitreal VCN-01 in retinoblastoma.
• Plan for a potential Phase 3 clinical trial of VCN-01 in PDAC, based on guidance from FDA and EMA.
• Advance the VCN-01 program in retinoblastoma, including potential submission of a formal protocol under a US IND.
• Expand GMP scale-up manufacturing activities for VCN-01.
• Continue supporting other preclinical and discovery initiatives, including VCN-X and THERICEL programs.
• Actively pursue additional equity or debt financing, private placements, public offerings, partnerships, and collaborations to fund future operations and clinical trials.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.

Key Dates

Recommendation

While the clinical data for VCN-01 in pancreatic cancer and retinoblastoma are highly promising and represent significant scientific advancements for a clinical-stage biotech, the company faces severe financial challenges. The 'going concern' warning, the explicit statement of insufficient cash for the next twelve months, and the deferral of a key milestone payment to Grifols highlight a precarious liquidity position. Investors should hold to monitor the company's ability to successfully secure the substantial additional funding required to advance its lead programs through pivotal trials and towards commercialization. Success in these areas could significantly de-risk the investment and unlock substantial value, but the current financial uncertainty warrants caution and a wait-and-see approach.

Keywords

Oncology, Biologics, Clinical-stage, VCN-01, Pancreatic Cancer, Retinoblastoma, Oncolytic Virus, Adenovirus, Phase 2b, Phase 1, Biotechnology, Drug Development, SEC Filing, 10-Q, Financial Health, Going Concern, Capital Raise, SYN-004, SYN-020, Rare Pediatric Drug Designation, Fast Track Designation, Orphan Drug Designation